ES2102154T3 - Inhibicion de trombina. - Google Patents

Inhibicion de trombina.

Info

Publication number
ES2102154T3
ES2102154T3 ES94309472T ES94309472T ES2102154T3 ES 2102154 T3 ES2102154 T3 ES 2102154T3 ES 94309472 T ES94309472 T ES 94309472T ES 94309472 T ES94309472 T ES 94309472T ES 2102154 T3 ES2102154 T3 ES 2102154T3
Authority
ES
Spain
Prior art keywords
thrombin inhibition
inhibition
trombine
pirrolidine
hexamethyleneamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94309472T
Other languages
English (en)
Inventor
Daniel Jon Sall
Gerald Floyd Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2102154T3 publication Critical patent/ES2102154T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

UN METODO DE INHIBICION DE TROMBINA Y SU TRATAMIENTO DE ENFERMEDADES Y CONDICIONES QUE CONSISTE EN ADMINISTRAR A UN HUMANO QUE LO REQUIERE UNA CANTIDAD EFECTIVA DE UN COMPUESTO QUE TIENE LA FORMULA (I) EN LA QUE R1 Y R3 SON INDEPENDIENTEMENTE HIDROGENO, CH3, -CO-(ALQUILO DE C1 A 3) O CO-AR DONDE AR ES FENILO OPCIONALMENTE SUSTITUIDO; R2 SE ELIGE A PARTIR DEL GRUPO QUE CONSISTE EN PIRROLIDINA, HEXAMETILENOAMINO, Y PIPERIDINO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE SOLVATO DE ESTE.
ES94309472T 1993-12-21 1994-12-19 Inhibicion de trombina. Expired - Lifetime ES2102154T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,394 US5441965A (en) 1993-12-21 1993-12-21 Methods of inhibiting thrombin

Publications (1)

Publication Number Publication Date
ES2102154T3 true ES2102154T3 (es) 1997-07-16

Family

ID=22623580

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94309472T Expired - Lifetime ES2102154T3 (es) 1993-12-21 1994-12-19 Inhibicion de trombina.

Country Status (21)

Country Link
US (3) US5441965A (es)
EP (1) EP0664126B1 (es)
JP (1) JPH07223947A (es)
KR (1) KR950016744A (es)
CN (1) CN1078070C (es)
AT (1) ATE150308T1 (es)
AU (1) AU693822B2 (es)
CA (1) CA2138493A1 (es)
CZ (1) CZ287725B6 (es)
DE (1) DE69402173T2 (es)
DK (1) DK0664126T3 (es)
ES (1) ES2102154T3 (es)
GR (1) GR3023537T3 (es)
HU (1) HU224915B1 (es)
IL (1) IL112048A (es)
NO (1) NO313081B1 (es)
NZ (1) NZ270185A (es)
RU (1) RU94045846A (es)
TW (1) TW321601B (es)
UA (1) UA29446C2 (es)
ZA (1) ZA9410084B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
EP0710116B1 (en) 1993-05-13 2008-09-03 Poniard Pharmaceuticals, Inc. Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
US5840747A (en) * 1995-06-07 1998-11-24 Eli Lilly And Company Calcium channel antagonists
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
ES2180702T3 (es) * 1995-06-07 2003-02-16 Lilly Co Eli Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
DE69634045T2 (de) 1995-10-31 2005-05-19 Eli Lilly And Co., Indianapolis Antithrombotische diamine
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
AU7470098A (en) 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
JP2002513415A (ja) 1997-04-30 2002-05-08 イーライ・リリー・アンド・カンパニー 抗血栓剤
DE69824410T2 (de) 1997-04-30 2005-06-02 Eli Lilly And Co., Indianapolis Antithrombosemittel
JP2002514217A (ja) 1997-04-30 2002-05-14 イーライ・リリー・アンド・カンパニー 抗血栓物質
US6103740A (en) * 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
TR200002855T2 (tr) * 1998-04-08 2000-12-21 Eli Lilly And Company Raloksifenin solunum yolu ile veya burundan uygulanması.
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
WO1999065489A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
EP0997460B1 (en) * 1998-10-28 2002-12-11 Eli Lilly And Company Benzothiophene compounds as antithrombotic agents and intermediates
IL146284A0 (en) 1999-05-04 2002-07-25 Strakan Ltd Androgen glycosides and pharmaceutical compositions containing the same
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
US5441965A (en) 1995-08-15
US5688813A (en) 1997-11-18
CA2138493A1 (en) 1995-06-22
NO313081B1 (no) 2002-08-12
AU8155894A (en) 1995-06-29
EP0664126A1 (en) 1995-07-26
TW321601B (es) 1997-12-01
ATE150308T1 (de) 1997-04-15
CZ322694A3 (en) 1995-09-13
KR950016744A (ko) 1995-07-20
EP0664126B1 (en) 1997-03-19
AU693822B2 (en) 1998-07-09
DE69402173D1 (de) 1997-04-24
RU94045846A (ru) 1996-10-20
GR3023537T3 (en) 1997-08-29
UA29446C2 (uk) 2000-11-15
HUT71344A (en) 1995-11-28
HU224915B1 (en) 2006-04-28
NZ270185A (en) 1997-07-27
NO944932D0 (no) 1994-12-19
IL112048A (en) 1999-03-12
US5508292A (en) 1996-04-16
CN1107704A (zh) 1995-09-06
DK0664126T3 (da) 1997-09-01
CN1078070C (zh) 2002-01-23
HU9403675D0 (en) 1995-02-28
ZA9410084B (en) 1996-06-19
NO944932L (no) 1995-06-22
JPH07223947A (ja) 1995-08-22
DE69402173T2 (de) 1997-07-17
IL112048A0 (en) 1995-03-15
CZ287725B6 (en) 2001-01-17

Similar Documents

Publication Publication Date Title
ES2102154T3 (es) Inhibicion de trombina.
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
ES2194986T3 (es) Compuestos de carbonil-piperazinilo y piperidinilo que inhiben la farnesil-protein-transferasa.
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
ES2101449T3 (es) Inhibicion de la seborrea y el acne.
UA26930C2 (uk) Засіб для іhгібуваhhя еhдометріозу
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
NO943873L (no) Hemming av bruskdegradering
DK0652004T3 (da) Fremgangsmåder til behandling af resistente neoplasmer
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
MX9709466A (es) Medicamento para inhibir el melanoma.
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
ATE203406T1 (de) Hemmung von hirsutismus und alopecia bei frauen
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 664126

Country of ref document: ES